Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

FY26: The sun sets on the growth story

Clinuvel Pharmaceuticals
3:27pm
August 28, 2026
CUV's FY26 result was soft, delivering the first annual revenue decline in the company’s history. The bigger story, though, is the Board's open consideration of a full Nasdaq listing and an ASX delisting. We lower our EPP assumptions, which have taken a competitive hit. FY26 earnings were flattered by R&D timing that we expect to reverse in FY27, and the long-term case now rests almost entirely on December's Vitiligo top-line. A$252m cash is the floor. We move to a HOLD (from Speculative Buy), with a lower target price of A$10 (from A$13). Our bear case is ~$7 on a Vitiligo failure.

1H26: looking ahead to the Dec-Q

29 Metals
3:27pm
August 28, 2026
1H26 EBITDA of $30.5m beat MorgansF by +8% but was a 20% miss to consensus. Importantly, the balance sheet remains solid with $202m of liquidity. Golden Grove is now approaching an inflection point as 29M moves closer to Xantho Extended coming back online, along with new ore sources from Gossan Valley and Oizon in Dec-Q. We maintain a HOLD rating with a A$0.35ps target price (previously A$0.26).

FY26: Engine rebuilt, but not yet in gear

Mach7 Technologies
3:27pm
August 28, 2026
The market should be broadly comfortable with the result given recent trading updates, but new contract delivery remains the key requirement before investors are likely to begin marking the stock materially higher. Revenue and OPEX landed broadly in line with guidance, while the NPAT miss was driven by a A$1.9m restructuring charge and a weaker tax benefit rather than deterioration in the core subscription business. Moderate increase in target price due to model roll-forward, lower share count, and leaner-than-expected cost base. Our target price rises to A$0.48 (from A$0.44) and we retain our Buy recommendation. Upside potential to target presents an opportunity but needs new contract momentum to spark renewed interest.

GMV acceleration becoming noteworthy

Airtasker
3:27pm
August 28, 2026
Airtasker's (ART) FY26 result was broadly in line with our expectations. Group revenue grew ~10% on pcp to A$57.8m (marketplaces revenue ex-OneFlare +15.5% to A$52m), and its earlier stage offshore marketplaces (UK/US) showed accelerating momentum and strong topline growth (+55%/150% respectively). ART also announced media deals with OML and Nova, extending the brand investment runway (media inventory to deploy from FY27 now ~A$24m). We make several changes to our assumptions across the forecast period (details below). Our price target remains unchanged at A$0.47. We retain our BUY recommendation.

A tight run

ImpediMed
3:27pm
August 28, 2026
IPD posted FY26 results which were lower than our forecasts. IPD completed a $15m capital raise providing an opportunity to grow SOZO placements in the US. The cadence of growth needs to accelerate for IPD to achieve break-even. We have revised forecasts down with a resultant adjustment to our TP, now $0.009 (was $0.01). We move to a HOLD recommendation (from SPECULATIVE BUY) while we wait to see growth in the SOZO installed base.

A tale of two halves

Camplify Holdings
3:27pm
August 28, 2026
CHL’s FY26 result was largely pre-released. However, while bookings late in the year were clearly impacted by macro and geopolitical events (e.g. fuel security concerns), the cost-out achieved in a softer top-line environment was a net positive and looks to have structurally reset the cost base going forward. CHL achieved positive EBITDA of A$0.3m for the full year on revenue of ~A$39m (-7% on pcp). While ANZ is showing some early signs of recovery (future bookings having risen to a degree), Europe remains a drag. Our DCF/multiples derived valuation and price target remains at A$0.70, and we retain our BUY recommendation.

FY26 result: Dreaming of larger jackpots

Jumbo Interactive
3:27pm
August 28, 2026
Jumbo Interactive (JIN) delivered underlying EBITDA of $85.2m (+25%) and NPATA of $50.6m (+20%), landing above the top of the July pre-release, despite a second consecutive year of historically weak jackpots in Australia. Despite this, the stock closed 3% lower on the day, likely reflecting the uncertainty around Brightstar and FY27 guidance that sat below market expectations in parts, which we regard as conservative. International (Managed Services + Prize Draws) is scaling well, contributing $30.3m vs $7.0m in FY25, while Australia fell 10% on continued large jackpot softness. Following the result, our FY27-28F EPSA estimates reduce 2-4%, and we forecast JIN to return to a net cash position by FY29. We retain a BUY recommendation, with a revised target price of $9.81 (was $10.25).

FY26: Broadly in line. Fuel still the one to watch in 27

Qantas Airways
3:27pm
August 28, 2026
Strength in the mix - QAN delivered a broadly in-line FY26 result despite a significant fuel cost headwind in 2H26, with a stronger-than-expected performance from Jetstar offsetting softer Domestic earnings. Group Underlying PBT of $2.06bn finished ~3% ahead of consensus, highlighting the resilience and diversification of the earnings base. TRASK tailwind emerges - QAN expects Domestic and International TRASK to increase 8-10% in 1H27 while Group capacity remains broadly flat, pointing to a more supportive revenue backdrop despite elevated fuel costs. We maintain our ACCUMULATE rating with a reduced-price target of A$10.60ps (previously $11.50).

FY26 result: Wildcard Round ready

BETR Entertainment
3:27pm
August 28, 2026
BETR Entertainment (BBT) finished the year strongly, with normalised EBITDA of $6.1m in the second half against guidance of $5m to $8m, a $19.3m swing on the first half. Full year normalised EBITDA of -$7.1m was a touch below our -$6.2m, with a gross profit beat offset by a higher cost of doing business. Encouragingly, current trading remains healthy. Through the first eight weeks of FY27, turnover is up more than 20%, new customers have almost doubled, CPA is down 31% and promotional cost is down 9%, all excluding the FIFA World Cup. The company announced the launch of its new first to market 'Wildcards' same game multi (SGM) feature that will launch during the Wildcard AFL round this weekend. Our EBITDA estimates increase 2.6% in FY27 and 3.5% in FY28. We maintain our BUY recommendation, with an unchanged target price of $0.36.

Constructing Confidence in FY27 and beyond

FDC Consolidated Holdings
3:27pm
August 27, 2026
FDC started listed life with a modest ~2% NPAT norm beat vs prospectus forecasts and FY27 prospectus forecasts reaffirmed. With 89% of FY27 revenue secured as at 30 June, this in our view significantly de-risks FY27 and increases our confidence in upside risk to forecasts. We retain our ACCUMULATE rating and increase our price target to $4.27 (from $3.97).

News & insights

Rate rises, class actions and CEO exits. Morgans adviser Dianne Colledge explains what is moving share prices on the ASX and what it means for investors.
Read more
Following the latest RBA meeting, Governor Michelle Bullock reinforced the Bank's focus on excess demand, labour market conditions and productivity, while suggesting current financial conditions are restrictive enough to return inflation to target.
Read more
A simple measure of hours worked can provide valuable insights into GDP growth. We examine why the Australian economy is slowing, what recent labour force data reveals, and the implications for interest rates.
Read more